Prestige Consumer Healthcare Inc (PBH)
ROA
Obliczenia
|
2024/Q3 (31 gru 2023) |
2024/Q2 (30 wrz 2023) |
2024/Q1 (30 cze 2023) |
2023/Q4 (31 mar 2023) |
2023/Q3 (31 gru 2022) |
2023/Q2 (30 wrz 2022) |
2023/Q1 (30 cze 2022) |
2022/Q4 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -80 671 | -81 766 | -84 302 | -82 306 | 210 332 | 208 596 | 202 898 | 205 381 |
| Aktywa razem | w tys. USD | 3 339 750 | 3 332 870 | 3 345 580 | 3 353 730 | 3 749 770 | 3 678 510 | 3 682 230 | 3 670 680 |
| ROA | -2,42% | -2,45% | -2,52% | -2,45% | 5,61% | 5,67% | 5,51% | 5,60% |
2024/Q3 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-80 671K ÷ $3 339 750K
= -2,42%
Analiza porównawcza
2024/Q3
Nazwa spółki
Symbol
ROA
Prestige Consumer Healthcare Inc
PBH
-2,42%
Amphastar Pharmaceuticals Inc
AMPH
9,09%
Catalyst Pharmaceuticals Inc
CPRX
15,19%
Corcept Therapeutics Inc
CORT
17,08%
Cytokinetics Inc
CYTK
-63,84%
Harmony Biosciences Holdings Inc
HRMY
15,88%
Ironwood Pharmaceuticals Inc
IRWD
-212,76%
Pacira BioSciences Inc
PCRX
2,66%
Schrodinger Inc
SDGR
5,07%
Supernus Pharmaceuticals Inc
SUPN
0,10%
Xencor Inc
XNCR
-13,23%